Elias Tjärnhage

• Tjärnhage, Elias; Våtsveen, Thea Kristin; Raki, Melinda; Nemazee, David; Farhan, Hesso & Munthe, Ludvig Andre [Vis alle 7 forfattere av denne artikkelen] (2026). Repurposing ALK inhibitors as influenza and corona virus antivirals targeting lymphocyte tyrosine kinase (LTK). Virus Research. ISSN 0168-1702. 370. doi: 10.1016/j.virusres.2026.199759. Fulltekst i vitenarkiv
• Anderson, Ane Marie; Tjärnhage, Elias; Hinke, Daniëla Maria; Braathen, Ranveig; Grødeland, Gunnveig & Bogen, Bjarne (2025). DNA vaccines targeting hemagglutinin from 18 subtypes of influenza A virus to antigen-presenting cells confer broad protection. Molecular Therapy Nucleic Acids. 37(1). doi: 10.1016/j.omtn.2025.102814. Fulltekst i vitenarkiv Vis sammendrag

  Novel vaccines that confer broad protection against influenza A viruses (IAVs) are urgently needed. Hemagglutinin (HA) is the major influenza antigen targeted by protective immune responses. We have here developed a DNA vaccine that simultaneously presents HA from 18 subtypes of IAV to the immune system. The vaccine consists of a DNA plasmid mixture that encodes a variety of dimeric vaccine proteins. Each dimer expresses two different HAs, as well as a targeting moiety directing the vaccine protein to antigen-presenting cells (APCs). When the vaccine proteins were targeted toward chemokine receptors 1, 3, and 5 (CCR1/3/5) on APC by means of macrophage inflammatory protein 1-alpha (MIP1α) (CCL3), vaccinated mice were broadly protected against infection with H1N1, H3N2, H5N1, and H7N1 influenza viruses. Furthermore, antibody-mediated protection against H1N1 was maintained when the H1 antigen was removed from the plasmid mixture, indicating that the diversity of HAs in the mixture promoted formation of antibodies specific for shared, conservative epitopes. The results may guide the development of a broadly protective influenza A vaccine for humans

• Anthi, Aina Karen; Kolderup, Heidi Anette; Vaage, Eline Benno; Bern, Malin C.; Benjakul, Sopisa & Tjärnhage, Elias [Vis alle 32 forfattere av denne artikkelen] (2025). An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models. Nature Communications. 16(1), s. 1–16. doi: 10.1038/s41467-025-59353-6. Fulltekst i vitenarkiv Vis sammendrag

  Although vaccines are usually given intramuscularly, the intranasal delivery route may lead to better mucosal protection and limit the spread of respiratory virus while easing administration and improving vaccine acceptance. The challenge, however, is to achieve delivery across the selective epithelial cell barrier. Here we report on a subunit vaccine platform, in which the antigen is genetically fused to albumin to facilitate FcRn-mediated transport across the mucosal barrier in the presence of adjuvant. Intranasal delivery in conventional and transgenic mouse models induces both systemic and mucosal antigen-specific antibody responses that protect against challenge with SARS-CoV-2 or influenza A. When benchmarked against an intramuscularly administered mRNA vaccine or an intranasally administered antigen fused to an alternative carrier of similar size, only the albumin-based intranasal vaccine yields robust mucosal IgA antibody responses. Our results thus suggest that this needle-free, albumin-based vaccine platform may be suited for vaccination against respiratory pathogens.

• Tjärnhage, Elias; Brown, Diamond; Bogen, Bjarne; Andersen, Tor Kristian & Grødeland, Gunnveig (2023). Trimeric, APC-Targeted Subunit Vaccines Protect Mice against Seasonal and Pandemic Influenza. Journal of Virology. ISSN 0022-538X. 97:e01694-22(2), s. 1–16. doi: 10.1128/jvi.01694-22. Fulltekst i vitenarkiv Vis sammendrag

  Subunit vaccines present only selected viral proteins to the immune system and allow for safe and easy production. Here, we have developed a novel vaccine where influenza hemagglutinin is presented in the natural trimeric form and then steered toward antigen-presenting cells for increased immunogenicity. We demonstrate efficient induction of antibodies and T-cell responses, and demonstrate that the vaccine format can protect mice against influenza subtypes H1N1, H5N1, and H7N1.

Se alle arbeider i NVA

• Ruso-Julve, Fulgencio; Sakya, Siri Aastedatter; Kolderup, Anette; Tjärnhage, Elias; Benjakul, Sopisa & Nilsen, Jeannette [Vis alle 10 forfattere av denne artikkelen] (2024). Engineered albumin as an effector negative scaffold for tailored design of long acting antibody fragment fusions. European Journal of Immunology. ISSN 0014-2980. 54, s. 802–802. Fulltekst i vitenarkiv
• Ruso-Julve, Fulgencio; Sakya, Siri A; Kolderup, Heidi Anette; Tjärnhage, Elias; Benjakul, Sopisa & Nilsen, Jeannette [Vis alle 10 forfattere av denne artikkelen] (2024). Engineered human albumin as an effector negative scaffold for tailored design of long-acting antibody fragment fusions. Fulltekst i vitenarkiv
• Skogstrøm, Lene; Grødeland, Gunnveig & Tjärnhage, Elias (2023). Ny influensavaksine utviklet i Norge: Kan bli brukt ved fremtidige pandemier. [Journal]. Aftenposten. Fulltekst i vitenarkiv
• Anthi, Aina Karen; Kolderup, Heidi Anette; Vaage, Eline Benno; Bern, Malin C.; Benjakul, Sopisa & Tjärnhage, Elias [Vis alle 30 forfattere av denne artikkelen] (2023). A novel non-invasive FcRn-targeted mucosal vaccine strategy. Fulltekst i vitenarkiv
• Grødeland, Gunnveig & Tjärnhage, Elias (2023). Ny influensavaksine for bedre fremtidig beskyttelse. Ekspertsykehuset OUS. Fulltekst i vitenarkiv
• Anthi, Aina Karen; Kolderup, Heidi Anette; Vaage, Eline Benno; Bern, Malin C.; Benjakul, Sopisa & Tjärnhage, Elias [Vis alle 30 forfattere av denne artikkelen] (2023). A non-invasive subunit vaccine technology targeting FcRn induces protective mucosal and systemic antibody immunity in mouse models. Fulltekst i vitenarkiv
• Anthi, Aina Karen; Kolderup, Heidi Anette; Vaage, Eline Benno; Bern, Malin C.; Benjakul, Sopisa & Tjärnhage, Elias [Vis alle 30 forfattere av denne artikkelen] (2023). A novel non-invasive FcRn-targeted mucosal vaccine strategy. Fulltekst i vitenarkiv
• Anthi, Aina Karen; Vaage, Eline Benno; Bern, Malin C.; Benjakul, Sopisa; Tjärnhage, Elias & Lode, Heidrun Elisabeth [Vis alle 29 forfattere av denne artikkelen] (2023). A non-invasive subunit vaccine technology targeting FcRn induces protective mucosal and systemic antibody immunity in mouse models. Fulltekst i vitenarkiv

Se alle arbeider i NVA